SLC1A4 Deficiency is a neurological disorder caused by mutations in the SLC1A4 gene, affecting the transport of the amino acid L-serine into the brain. It has been identified more frequently in Ashkenazi Jewish families.
SLC1A4 encodes a protein called ASCT1, a neutral amino acid transporter expressed in astrocytes — the support cells of the brain. ASCT1 is responsible for shuttling the amino acid serine from astrocytes into neurons.
Serine is essential for the synthesis of proteins, membrane lipids, and neurotransmitters. In the developing brain, adequate serine is critical for neuronal growth, myelination, and synaptic function.
The most common pathogenic variant in the Ashkenazi Jewish population is a founder mutation: p.Glu256Lys (c.766G>A). When both parents pass on this mutation with a single amino acid change, it disrupts the transporter's function, severely limiting serine supply to neurons during critical developmental windows.
SLC1A4 Deficiency typically presents in infancy and early childhood. The spectrum and severity can vary, but common features include:
MRI typically shows low brain volume, a thin corpus callosum, and delayed myelination — all consistent with impaired brain development during early life.
SLC1A4 Deficiency is diagnosed through genetic testing — specifically whole exome sequencing or targeted gene panels. These tests are typically pursued when a child has significant developmental delay that cannot be explained by blood work, brain imaging, or other standard diagnostic tests.
Because SLC1A4 Deficiency follows autosomal recessive inheritance, both parents must be carriers for a child to be affected. Each pregnancy of two carriers carries a 25% chance of an affected child.
The Ashkenazi Jewish community has the highest known carrier rate — approximately 1 in 100 individuals carries the founder mutation. This makes population-based carrier screening both feasible and critically important.
💡 Carrier screening for SLC1A4 is now included in expanded Jewish genetic disease panels offered by some clinical genetic testing laboratories. Ask your OB/GYN or genetic counselor about testing.
Couples who are both carriers have options including prenatal diagnosis (CVS or amniocentesis) and preimplantation genetic testing (PGT) with IVF to select unaffected embryos.
The gene, the protein, the mutation, and the biochemical mechanism are well characterized. Carrier screening is available and accurate.
A natural history study is currently in progress to systematically document the disease course, range of severity, and outcomes for patients with SLC1A4 Deficiency. This study will provide the foundation needed to design future clinical trials and evaluate potential treatments.
Despite growing understanding of SLC1A4 Deficiency, no effective treatments exist. Developing therapies — whether gene therapy, small molecule approaches, or other interventions — requires sustained research investment, animal models, and ultimately clinical trials. That work starts now, with your support.